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Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that belong to the nuclear hormone
receptor superfamily. PPARα is mainly expressed in the liver, where it activates fatty acid catabolism. PPARα activators have been
used to treat dyslipidemia, causing a reduction in plasma triglyceride and elevation of high-density lipoprotein cholesterol. PPARδ
is expressed ubiquitously and is implicated in fatty acid oxidation and keratinocyte diﬀerentiation. PPARδ activators have been
proposed for the treatment of metabolic disease. PPARγ2 is expressed exclusively in adipose tissue and plays a pivotal role in
adipocyte diﬀerentiation. PPARγ is involved in glucose metabolism through the improvement of insulin sensitivity and represents
a potential therapeutic target of type 2 diabetes. Thus PPARs are molecular targets for the development of drugs treating metabolic
syndrome.However,PPARsalsoplayaroleintheregulationofcancercellgrowth.Here,wereviewthefunctionofPPARsintumor
growth.
Copyright © 2008 Keisuke Tachibana et al. This is an open access article distributed under the Creative Commons Attribution
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1. INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are li-
gand-activated transcription factors that belong to the nu-
clear hormone receptor superfamily [1]. PPARs bind to a
direct repeat of two hexanucleotides, spaced by one or two
nucleotides (the DR1 or DR2 motif) as heterodimers with
the retinoid X receptor (RXR), and activate several target
genes [2–4]. These peroxisome proliferator responsive ele-
ments (PPREs) are found in various genes that are involved
in lipid metabolism and energy homeostasis, including lipid
storage or catabolism, and fatty acid transport, uptake, and
intracellular binding [5]. Three subtypes, PPARα,P P A R δ
(also known as PPARβ), and PPARγ, have been identiﬁed
and these subtypes with a high degree of sequence con-
servation of each subtype across various species have been
characterized. The DNA-binding domains of the three sub-
types are 80% identical, while their ligand-binding domains
exhibit a lower degree (approximately 65%) of identity
(Figure 1). Consistent with this relatively high divergence
among the subtype-speciﬁc ligand-binding domains, diﬀer-
ential activation of PPARs by endogenous and exogenous
compounds may account for the speciﬁc biological activity
of the three PPAR subtypes [6, 7].
PPARα is expressed in the liver, kidney, small intestine,
heart, and muscle, where it activates fatty acid catabolism
and is involved in the control of lipoprotein assembly [8].
PPARα is activated by several molecules, such as long chain
unsaturated fatty acids, eicosanoids, and hypolipidemic dr-
ugs (e.g., fenoﬁbrate) [9–12]. PPARα activators have been
used to treat dyslipidemia, causing a reduction in plasma
triglyceride and elevation of high-density lipoprotein (HDL)
cholesterol [13, 14]. PPARδ is expressed ubiquitously and is
implicated in fatty acid oxidation, keratinocyte diﬀerentia-
tion, wound healing, and the response of macrophages for
very low-density lipoprotein [15–19]. PPARδ activators have
been proposed for the treatment of metabolic disease and are
under clinical trial [20, 21]. There are two PPARγ isoforms:
PPARγ1a n dγ2[ 22, 23]. PPARγ2 ,w h i c hi sg e n e r a t e db y
alternative splicing, contains an additional 28 amino acids at
the N-terminal compared to PPARγ1. PPARγ3 is a splicing
variant of PPARγ1 and gives rise to the same protein [24].2 PPAR Research
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Figure 1: The general features of human PPARs. (a) Structure and functional domain of human PPARs. A/B, C, D, and E/F indicate N-
terminal A/B domain containing a ligand-independent activation function 1, DNA-binding domain (DBD), hinge region, and C-terminal
ligand-binding domain (LBD), respectively. The number inside each domain corresponds to the percentage of amino acid sequence identity
ofhumanPPARδ andPPARγ relative to PPARα.(b)PPAR/RXRheterodimersbindtoaPPRElocatedinthepromoteroftargetgenesthrough
the DBD. Unliganded PPAR associates with the corepressor complex. In the presence of ligand, the ligand-bound LBD associates with the
coactivator complex.
PPARγ2 is expressed exclusively in adipose tissue and plays a
pivotal role in adipocyte diﬀerentiation, lipid storage in the
white adipose tissue, and energy dissipation in the brown
adipose tissue [22, 25]. On the other hand, PPARγ1i se x -
pressed in the colon, the immune system (e.g., monocytes
and macrophages), and others. Except for the function
of PPARγ2 in adipose tissue, PPARγ also participates in
inﬂammation, cell cycle regulation, and other functions
[26]. PPARγ is involved in glucose metabolism through the
improvement of insulin sensitivity and represents a potential
therapeutic target of type 2 diabetes [26]. Indeed, insulin-
sensitizingthiazolidinedione(TZD)drugsarePPARγ ligands
[27]. Thus PPARs are molecular targets for the development
of drugs to treat type 2 diabetes and metabolic syndrome.
On the other hand, PPARs also play a role in the regulation
of cancer cell growth.
2. PPARα AND CANCER
Fibrates, which are relatively weak PPARα ligands, are useful
for the treatment of dyslipidemia [7, 9–11]. Fibrates lower
serum triglyceride levels and increase HDL levels through
the activation of PPARα [5]. PPARα induces lipoprotein
lipase (LPL) expression, reduces the expression levels of
apolipoprotein C-III (ApoC-III), a natural LPL inhibitor,
and stimulates the uptake of cellular fatty acids and the
conversion of fatty acids to acyl-CoA derivatives [5, 28, 29].
These catabolism functions are mediated by upregulating
the expression of a series of genes-related carbohydrate and
lipid metabolism [5, 30]. In addition, PPARα increases the
expressions of ApoA-I and ApoA-II, resulting in raising HDL
c h o l e s t e r o ll e v e l si nh u m a n s[ 31, 32]. Thus PPARα plays
a central role in the control of fatty acid and lipoprotein
metabolism, and improves plasma lipid proﬁles. Although
peroxisome proliferators have carcinogenic consequences in
the liver of rodents, epidemiological studies suggest that
similar eﬀects are unlikely to occur in humans [10, 33–36].
Several mechanisms have been proposed to explain the
carcinogenesis of peroxisome proliferators in rodents. Peters
et al. reported that wild-type mice treated with the Wy-
14,643 showed increase of replicative DNA synthesis in hep-
atic cells and developing liver tumors with 100% incidence,
whereas PPARα- n u l lm i c ew e r er e f r a c t o r yt ot h i se ﬀect [37].
Peroxisome proliferators increase the peroxisome volume
and number and result in an increase in hydrogen peroxide
(H2O2)l e v e l s[ 38–40]. These eﬀects may be mediated in
partbytheincreasedexpressionofperoxisomalenzymesthat
produce H2O2,s u c ha sa c y lC o Ao x i d a s e( A C O )[ 39–41].
PPARα upregulates the expression levels of ACO via PPRE
in the promoter region [42, 43]. A stably transfected AfricanKeisuke Tachibana et al. 3
green monkey kidney cells (CV-1) overexpressing rat ACO
increased H2O2 production, formed transformed foci, and
grew eﬃciently in soft agar when the cells were treated
with linoleic acid [44]. Furthermore, when these cells were
transplanted into nude mice, these cells formed solid tumors
[44]. An increase of intracellular levels of H2O2 c o u l dl e a dt o
DNA damage via a variety of mechanisms [45]. Any reduced
ironpresentcancatalyzethecleavageofH2O2,viatheFenton
reaction, to produce hydroxyl radicals (HO•)[ 46]. The
HO• attacks guanine residues, producing residues of 8-oxo-
7,8-dihydroguanine (8-oxoguanine). When DNA synthesis
occurs before the 8-oxoguanine is repaired, this damaged
base will have a chance to pair with adenine nucleotide, re-
sulting in a mutation in the daughter cells [47]. In addition,
antioxidants inhibit ciproﬁbrate-induced hepatic tumorige-
nesis by scavenging active oxygen [48]. Thus oxidative stress
by peroxisome proliferators acts as a driving force to malig-
nancy. The activation of PPARα also leads to increased hepa-
tocellular proliferation and inhibition of apoptosis. Chron-
ic administration of nafenopin, PPARα agonist, to mice
causes signiﬁcant increase in the liver weight, hepatic DNA
synthesis, and the development of hepatocellular carcinomas
[49]. Nafenopin treatment of primary cultures of adult rat
hepatocytes also stimulated DNA synthesis [50]. Indeed,
Peters et al. showed that mRNAs encoding cyclin-dependent
kinase (CDK) 1, CDK4, cyclin D1, and c-myc and their pro-
teins, which induce cell proliferation, increased in wild-type
mice fed by Wy-14,643 but not in PPARα- n u l lm i c e[ 51].
Increase of the average liver weight and the levels of mRNAs
encoding cell cycle regulation, such as CDK4, proliferating
cell nuclear antigen (PCNA) and cyclin B1, were also found
in wild-type mice fed by bezaﬁbrate, the less speciﬁc PPARα
agonist, and these eﬀects were not found in PPARα-null
mice [52]. Moreover, the treatment of the primary culture
of rat hepatocytes and the rat hepatoma cell line, FaO, with
nafenopin suppressed apoptosis [53, 54]. Thus the activation
of PPARα leads to the increase of oxidative stress, induction
of cell proliferation and inhibition of apoptosis, indicating
that PPARα increases hepatocarcinogenesis in mice.
A number of experimental observations suggest that
there is a species diﬀerence between rodents and humans in
the response to PPARα agonists, although the functional
diﬀerences of PPARα derived from species are not clear
(Table 1). One possible explanation for the diﬀerence is the
expression levels of PPARα in the liver. The expression levels
of PPARα in human liver are approximately one order less
than that observed in mouse liver [55]. Small expression
levels of PPARα could allow PPREs to be occupied by other
members of the nuclear receptor superfamily, such as RXR,
thechickenovalbuminupstreampromotertranscriptionfac-
tor I (COUP-TFI), COUP-TFII, hepatocyte nuclear factor-4
(HNF4), retinoic acid receptor (RAR), and thyroid hormone
receptor (TR), and aﬀect responsiveness to peroxisome pro-
liferators [56–62]. We and others have shown that elevated
expression of PPARα in HepG2 cells dramatically increased
the expression of several target genes, such as 3-hydroxy-3-
methylglutaryl-CoAsynthase2(mitochondrial)(HMGCS2),
carnitine palmitoyltransferase 1A (CPT1A), and long chain
fatty acyl-CoA synthetase (ACS) [30, 63, 64]. In this way,
Table 1: Summary of the species diﬀerences of PPARα.
Human Rodent
PPARα expression levels + ++
PPARα variants Yes ?
Peroxisome proliferation +/− +
Fatty acid metabolism + +
Expression of cell cycle regulator genes +/− +
Expression of miRNA (let-7C) + −
Hepatocellular proliferation +/− +
Apoptosis + −
Liver tumor +/− ++
the lower expression levels of PPARα in human liver might
contribute to holding down peroxisome proliferation and
subsequent pathologic eﬀects. Another explanation is that
several PPARα variants, which lack the entire exon 6 or
contain mutations, are detected in human cells and these
variants act as a dominant negative regulator of PPAR-
mediated gene transcription [55, 65, 66]. But this has not
beenfoundinrodentsyet.OnePPARαvariantcontainingthe
mutation prevents the suppression of hepatocyte apoptosis
by nafenopin [55, 65, 66]. Thus the expression levels of
PPARα variants might aﬀect the response to peroxisome
proliferators. Next, there appears to be sequence diﬀerences
in the PPRE found in the promoter region of ACO. Osumi
et al. identiﬁed ACO to be a direct PPARα target gene and
a functional PPRE located in the proximal promoter of the
rat ACO gene [42]. In contrast to the rodent ACO gene
promoter, the human ACO gene promoter diﬀe r sa tt h r e e
bases within the PPRE from the rat ACO promoter and
appears refractory to PPARα [42, 67, 68]. This human PPRE
was unable to drive peroxisome proliferators-induced gene
transcription in cell-based assays [67–69]. Indeed, human
liver cell lines and primary hepatocytes did not induce
ACO mRNA by treatment with ﬁbrates or other PPARα
agonists [63, 64]. A similar pattern, such diﬀerences between
human and other species, was observed in the expression
of ApoA-I gene [31]. Fibrates inﬂuence the ApoA-I gene
expression, raising it in humans, and lowering it in rodents.
These diﬀerences are due to a combination of two distinct
mechanisms implicating the nuclear receptors PPARα and
Rev-erbα, a negative regulator of gene transcription [31].
The species-distinct regulation is due to sequence diﬀerences
in cis-acting elements in their respective promoters leading
to repression by Rev-erbα of rat ApoA-I and activation by
PPARα of human ApoA-I. There is a positive PPRE in the
human ApoA-I promoter but not in rats. The expression of
Rev-erbα is induced by ﬁbrates [3, 31]. In the case of rat,
this induction leads to the repression of the ApoA-I gene
expression through an Rev-erbα response element. On the
other hand, there is no Rev-erbα response element in the
h u m a nA p o A - Ig e n e[ 31]. Thus the sequence diﬀerences
in cis-acting elements cause the species-distinct regulation
of target genes expression by peroxisome proliferators.
However, the mechanism of the species diﬀerences is not
known in detail.4 PPAR Research
To determine the mechanism of species diﬀerence in
response to peroxisome proliferators, Gonzalez et al. gen-
erated a liver-speciﬁc PPARα humanized mouse line
(hPPARα
TetOﬀ mice) in which the human PPARα was expr-
essed in the liver in a PPARα-null background under the
control of the tetracycline (Tet) responsive regulatory system
[70–72]. The expression of several target genes encoding
peroxisomal and mitochondrial fatty acid metabolizing
enzymes were elevated in hPPARα
TetOﬀ mice fed Wy-14,643
orfenoﬁbrate,resultinginthedecreaseofserumtriglycerides
[70, 73]. However, the expressions of various genes involved
in cell cycle regulation (PCNA, c-myc, CDK1, CDK4, and
cyclins) in the liver were unaﬀected by Wy-14,643. In ad-
dition, hPPARα
TetOﬀ mice were resistant to Wy-14,643-
induced hepatocarcinogenesis [70, 73]. Recently, Shah et al.
showed that Wy-14,643 regulated mice hepatic MicroRNA
(miRNA) expression via a PPARα-dependent pathway [74].
miRNAsareaclassofnonprotein-coding,endogenous,small
RNAs, and regulate gene expression by translational repres-
sion and mRNA cleavage [75]. Some miRNAs regulate cell
proliferation and apoptosis processes that are important in
cancer formation [76]. The activation of PPARα with Wy-
14,643 inhibits the expression of miRNA let-7C, which func-
tions as a tumor suppressor gene [74]. let-7C degrades c-myc
mRNA by binding to 3’ untranslated region (UTR) of the c-
myc gene. Treatment of mice with Wy-14,643 showed that
let-7C expression was decreased and a subsequent increase
in c-myc was observed. Following an increase in c-myc,
the levels of the oncogenic mir-17 miRNA cluster were
increased [74]. In this way, inhibition of the let-7C signaling
cascade may lead to increased hepatocellular proliferation
and tumorigenesis. In contrast, hPPARα
TetOﬀ mice do not
exhibit downregulation of let-7C and induced c-myc and
mir-17 expression [74]. Furthermore, Yang et al. generated
another type of PPARα humanized mice, hPPARα
PAC mice,
that has the complete human PPARα gene sequence includ-
ing 5’ and 3’ ﬂanking sequences on a P1 phage artiﬁcial
chromosome (PAC) genomic clone, introduced onto the
mouse PPARα-null background [71]. Upon treatment with
the peroxisome proliferators (Wy-14,643 or fenoﬁbrate),
hPPARα
PAC mice exhibited peroxisome proliferation, lower-
ing of serum triglycerides, and induction of PPARα target
genes encoding enzymes involved in fatty acid metabolism.
However, let-7C expression was not decreased and the
expression levels of c-myc, cyclin D1 and CDK4 were not
increased [71]. Thus these observations suggest that the
species diﬀerences in response to peroxisome proliferators
could be due in part to a diﬀerential ability of the mouse
and human PPARα to suppress let-7C gene expression [74].
However, the mechanism involved in PPARα-dependent
repression of let-7C is unclear. The diﬀerences between the
wild-type mice and PPARα humanized mice could be caused
by the structural diﬀerences between human and mouse
PPARα and diﬀerential coactivator recruitment. However,
additional investigation is required to better understand
and clarify the mechanism of action of PPARα in causing
hepatocarcinogenesis.
3. PPARδ AND CANCER
T h er o l eo fP P A R δ in oncogenesis is controversial, especially
in colon cancer. Some reports show that PPARδ promotes
tumorigenesis by increasing cell proliferation. Indeed, the
levels of PPARδ mRNA are increased in both human and
rodent colorectal carcinomas [77, 78]. PPARδ is a potential
downstream target gene of the adenomatous polyposis coli
(APC)/β-catenin/T cell factor-4 (TCF-4) pathway [77]. APC
is a tumor suppressor gene and is mutated in familial
adenomatous polyposis (FAP) and most sporadic colorectal
tumors [79–83]. β-catenin, which binds to APC and axin in
a large protein complex, can be phosphorylated by glycogen
synthase kinase-3β (GSK3β) and is followed by ubiquiti-
nation and degradation. Mutation of APC results in the
accumulation of β-catenin, which in turn translocates to the
nucleus and associates with the transcription factor TCF-4
[84]. The β-catenin-TCF-4 transcription complex increases
the transcription of growth-promoting genes, such as c-myc
a n dc y c l i nD 1[ 85, 86]. The β-catenin-TCF-4 transcription
complex also activates the human PPARδ promoter activity
via TCF-4 binding sites, namely, APC suppresses the PPARδ
expression through the degradation of β-catenin [77]. K-Ras
mutation is found in colorectal cancer [80, 87]. Activation
mutations in Ras result in the activation of the mitogen-
activated protein kinase (MAPK) pathway and induce tumor
growth and progression [88]. The expression levels and
activityofPPARδ wereincreasedbytheinductionofmutated
K-Ras in conditionally K-Ras-transformed rat intestinal
epithelial cells [89]. Thus PPARδ is also a downstream target
gene of Ras/Raf/MAPK and extracellular signal-regulated
kinase (ERK) kinase (MEK)/ERK pathway [89]. In this way,
PPARδ may play a role in colon cancer.
Epidemiological studies have shown that nonsteroidal
anti-inﬂammatory drugs (NSAIDs), such as aspirin, indo-
methacin, and sulindac, reduce the overall number and
size of adenomas in patients with FAP. Healthy individuals
using NSAIDs regularly can lead to a 40–50% reduction in
the relative risk of developing colon cancer [90]. NSAIDs
inhibit cyclooxygenase (COX) activity and thereby reduce
prostaglandin synthesis [91]. COX is a key enzyme in ara-
chidonic acid metabolism and prostaglandin production.
COX catalyzes a two-step reaction that converts arachidonic
acid to prostaglandin H2 (PGH2), which in turn serves as
the precursor for the synthesis of all biologically active
prostaglandins, including PGD2,P G E 2,P G F 2α, prostacyclin
(PGI2), and thromboxane A2 (TXA2)[ 92]. COX exists in
two isoforms that are encoded by two separate genes. COX-1
is constitutively expressed in most tissues, on the other
hand, the expression of COX-2 is normally low or absent in
most tissues but is rapidly upregulated by proinﬂammatory
cytokines [93]. Expression of COX-2 is also elevated in col-
orectal cancer and in a subset of adenomas [94]. Moreover,
since both the introduction of the knockout mutation of
the COX-2 gene into ApcΔ716 mice, a model of human
FAP, and treating ApcΔ716 mice with NSAIDs reduce the
development of intestinal tumors, COX-2 inhibitors have
been considered as therapeutic agents for colorectal poly-
posis and cancer [95]. He et al. reported that NSAIDsKeisuke Tachibana et al. 5
inhibited the transcriptional activity of PPARδ by disruption
of the DNA binding ability of PPARδ/RXR heterodimers,
and ectopic expression of PPARδ in the human colorectal
cancer cell line, HCT116, protected the cells from sulindac-
induced apoptosis [77]. PPARδ and COX-2 mRNA are
expressed in similar regions in human colon cancer, and
the stable PGI2 analog, carbaprostacyclin (cPGI), acts as a
PPARδ ligand [11, 78]. Indeed, ectopic expression of COX-
2 and PGI synthase (PGIS) in the human osteosarcoma
cell line, U2OS, produced high levels of endogenous PGI2
and transactivation of PPARδ [78]. PGE2 levels are also
elevated in human colorectal cancers and adenomas, and
PGE2 increases the growth and motility of colorectal car-
cinoma cells [96, 97]. D. Wang et al. showed that PGE2
promoted resistance to serum starvation-induced apoptosis
of cultured human colon carcinoma cells, LS-174T, through
indirectly upregulation PPARδ transcriptional activity via
a phosphotidylinositol-3-kinase (PI3K)-Akt pathway [98].
Furthermore,PGE2 acceleratesintestinal adenomagrowthof
Apcmin mice,amodelofhumanFAPthatharborsamutation
in the apc gene, via PPARδ [98]. Xu et al. showed that PGE2
activated cytosolic phospholipase A2α (cPLA2α) through
PI3KorMAPKpathway,andsubsequentlycPLA2αenhanced
PPARδ activity in the human cholangiocarcinoma cells [99].
They also showed that PPARδ enhanced COX2 expression
and PGE2 production. This positive feedback loop may
play an important role in cholangiocarcinoma cell growth,
although it is not known whether this kind of positive
feedback loop exists in the colorectal cancer cells [99]. Thus
PPARδ induces the cell proliferation through the inhibition
ofapoptosis.However,sulindacsulﬁdeinducesapoptosisnot
only in wild-type HCT116, but also in HCT116 PPARδ-null
cell lines [100]. On the basis of these observations, although
NSAIDs may reduce tumorigenesis through the inhibition of
PPARδ activity, PPARδ is not a major mediator of sulindac-
mediated apoptosis.
Recent evidence supports the hypothesis that PPARδ
promotes tumor progression. HCT116 PPARδ-null cell lines
grew slightly more slowly than wild-type HCT116 cells, and
exhibited a decreased ability to form tumors compared with
wild-type mice when inoculated as xenografts in nude mice
[100]. Gupta et al. showed that exposure of Apcmin mice
to 10mg/kg of GW501516, a high-aﬃnity PPARδ-selective
agonist, led to a two-fold increase in polyp number in
the small intestine [101]. The most prominent eﬀect was
on polyp size, mice treated with the PPARδ activator had
a ﬁve-fold increase in the number of polyps larger than
2mm, suggesting that PPARδ activation primarily aﬀ-
ected the rate of polyp growth rather than initiating
polyp formation. Pretreatment of wild-type HCT116 cells
with GW501516 signiﬁcantly suppressed serum starvation-
induced apoptosis in a dose-dependent manner, but not
HCT116 PPARδ-null cells [101]. Furthermore, D. Wang et
al. showed that PPARd
−/−/Apcmin mice decreased intesti-
nal adenoma growth and inhibited the tumor-promoting
eﬀect of GW501516 [102]. They also showed that PPARδ
activation with GW501516 upregulated vascular endothelial
growth factor (VEGF) transcription, expression, and peptide
release in intestinal epithelial tumor cells, and subsequently
activated PI3K-Akt signaling [102]. Similar results were
obtained in the human endothelial cells [103, 104]. Piqueras
et al. showed that GW501516 induced VEGF mRNA and
peptide release, and thus PPARδ induced endothelial cell
proliferation and angiogenesis [103]. Stephen et al. showed
that the activation of PPARδ resulted in increased expression
of VEGF and its receptor fms-related tyrosine kinase 1
(FLT-1), and they suggested that PPARδ might initiate an
autocrine loop for cellular proliferation and possibly angio-
genesis[104].TheseresultsdemonstratethatVEGFmediates
the antiapoptotic eﬀects of PPARδ in intestinal epithelial
tumor cells by activating the PI3K-Akt cell survival pathway,
and the VEGF autocrine loop plays an important role
in cell survival. Diminished apoptosis is also linked to
downregulated 15-lipoxygenase-1 (15-LOX-1) expression in
colorectal cancer cells. 13-S-hydroxyoctadecadienoic acid
(13-S-HODE), which is the primary product of 15-LOX-1
metabolism of linoleic acid, inhibits cell proliferation and
inducescellcyclearrestandapoptosisintransformedcolonic
epithelial cells [105]. 15-LOX-1 protein expression and 13-
S-HODE intracellular levels are decreased in human colonic
tumors[105].Shureiqietal.showedthat13-S-HODEbound
to PPARδ and then downregulated PPARδ expression and
activation in colorectal cancer cells, DLD-1 and RKO, and
that the loss of PPARδ expression in HCT116 markedly
suppressed 13-S-HODE-mediated apoptosis [106]. 15-LOX-
1 expression also downregulated PPARδ expression and
transcriptional activity in these colorectal cancer cells [106].
Furthermore, NSAIDs increase 15-LOX-1 protein expression
and its product 13-S-HODE levels and downregulate PPARδ
expression in association with subsequent growth inhibition
and apoptosis [106, 107]. Thus it is considered possible that
PPARδ promotes the growth of colon cancers.
On the contrary, other reports suggest that ligand acti-
vation of PPARδ promotes the induction of terminal diﬀer-
entiation and inhibition of cell growth. PPARδ was found
in intestinal epithelial cells in both the normal intestine
and adenomas of Apcmin mice [101]. Reed et al. reported
that targeted deletion of the APC alleles in mouse intestines
decreasedtheexpressionlevelsofPPARδ mRNAandprotein,
although β-catenin and c-myc were increased [108]. Marin
et al. showed that PPARδ expression was reduced in both
the Apcmin mouse colon polyps and azoxymethane (AOM)-
treated wild-type mouse polyps, though the expression lev-
els of PPARδ mRNA in colonic epithelium were not dif-
ferent between Apcmin mice and wild-type mice with or
without AOM-treatment [109]. Several reports identiﬁed
that the transcription factor binding sites for AP-1,
CCAAT/enhancer-binding proteins, vitamin D receptor, and
others were found in human or mouse PPARδ promoter,
and these transcription factors regulated PPARδ expression
[16, 110, 111]. However, further investigation is required to
certify the regulation of PPARδ expression in cancer.
Hollingshead et al. reported that GW501516 and
GW0742, highly speciﬁc PPARδ ligands, did not increase the
growth of human colon cancer cell lines (HT-29, HCT116,
and LS-174T) and liver cancer cell lines (HepG2 and HuH7)
cultured in the presence or absence of serum [112]. In6 PPAR Research
addition, treatment of these cell lines with either GW501516
or GW0742 did not change the phosphorylation of Akt,
and no increase in the expression levels of COX2 or VEGF
were detected [112]. Similar results were observed in the
colon or liver of Apcmin mice treated with GW501516 or
GW0742 [109, 112]. Barak et al. showed that the average
number of intestinal polyps was not signiﬁcantly dif-
ferent between PPARd
+/+/Apcmin, PPARd
+/−/Apcmin,a n d
PPARd
−/−/Apcmin mice, although this study was limited to
a small number [113]. On the other hand, several studies
showed that colon polyp formation was enhanced in the
absence of PPARδ expression in both PPARd
−/−/Apcmin and
AOM-treated PPARd
−/− mice [108, 109, 114]. Moreover,
Marin et al. showed that the administration of GW0742
had no eﬀect on colon or small intestinal tumorigenesis
in either PPARd
−/−/Apcmin or PPARd
+/+/Apcmin mice as
compared with controls [109]. In addition, decrease of
colon polyp multiplicity was observed in PPARd
+/+ AOM-
treated mice administrated with GW0742 compared with
control wild-type mice. This eﬀect was likely due in part
to PPARδ-dependent induction of colonocyte diﬀerentia-
tion and enhancement of apoptosis [109]. Indeed, PPARδ
induces keratinocyte terminal diﬀerentiation, which nor-
mally opposes cell proliferation [115, 116]. Hatae et al.
also showed that intracellular PGI2,a ne n d o g e n o u sP P A R δ
ligand, formed by expressing PGIS in human embryonic
kidney293(HEK293)cells,promotedapoptosisbyactivating
PPARδ [117]. In this way, PPARδ inhibits tumor growth by
inducing apoptosis or diﬀerentiation.
Thus the conﬂicting reports in the literature suggest that
PPARδ either potentiates or attenuates colon cancer. Similar
discrepancies were observed in other tissues. Di-Po¨ ıe ta l .
showed that the activation of PPARδ inhibited apoptosis in
keratinocyte [118]. The activation of PPARδ by L-165041,
o n et y p eo fP P A R δ ligand, upregulates 3-phosphoinositide-
dependent kinase-1 (PDK1) and integrin-linked kinase
(ILK) gene expression via PPRE and downregulates phos-
phatase and tensin homolog (PTEN) protein expression,
and subsequently leads to the activation of Akt1 in a PI3K-
dependent manner in mouse primary keratinocytes and
human keratinocyte HaCaT cells [118]. Yin et al. showed
that PPARδ ligand GW501516 accelerated progestin- and
carcinogen-induced mouse mammary carcinogenesis [119].
Stephen et al. reported that PPARδ selective agonists stimu-
lated the proliferation of human breast and prostate cancer
cell lines and primary endothelial cells [104]. On the other
hand, Burdick et al. reported that ligand activation of
PPARδ with GW0742 inhibited the cell growth of either
human keratinocyte cell line N/TERT1 or mouse primary
keratinocytes[120].Inthesecells,ligandactivationofPPARδ
by GW0742 did not alter expression and/or modulation
of the PTEN/PDK1/ILK1/Akt pathway [120]. Girroir et al.
reported that both GW0742 and GW501516 inhibited the
growth of the human breast cancer cell line, MCF7, and
human melanoma cell line, UACC903 [121].
To date, however, the reason for the contradiction in
these observations is unclear. One explanation for these
conﬂicting results may be the ability of PPARδ to repress the
transcription of target genes. We and others observed that
unliganded PPARδ repressed target gene expression, though
ligand-activated PPARδ induced these genes [30, 122–124].
It has been reported that unliganded PPARδ bound to PPRE
andrecruitedcorepressors,suchasB-celllymphoma6(BCL-
6), silencing mediator for retinoid and thyroid hormone
receptor (SMRT), nuclear receptor corepressor (NCoR), and
others. On the other hand, liganded PPARδ is thought to
release the corepressor and form a complex with coactivators
[122–124]. Furthermore, binding of ligand to the PPARδ
or deletion of PPARδ expression may lead to the release
of BCL-6. Subsequently, BCL-6 represses the transcription
of a number of inﬂammatory cytokine genes [124]. Thus
the PPARδ activity may be inﬂuenced by the cellular envi-
ronment, such as the existence of PPARδ ligands, cofactors,
and others. From this viewpoint, the conﬂicting results may
be due to diﬀerences in the condition of cell cultures or
the genetic background of animal models. Secondly, pros-
taglandins, some of which act as PPAR ligands, have a
variety of biological activities. Prostaglandins, synthesized
via the COX pathway from arachidonic acid, are released
outside the cells and lead to changes in the cellular levels of
cyclic AMP and Ca2+ through binding to G-protein-coupled
receptors on the plasma membrane [90]. Indeed, Hatae et
al. suggested that cAMP produced by the PGI2-PGI receptor
(IP)-cAMP pathway might protect vascular endothelial cells
from intracellular PGI2-PPARδ-mediated apoptosis [117].
On the other hand, Fauti et al. showed that the ectopic
expression of COX-2 and PGIS in HEK293 cells results in
a dramatic induction of PGI2 synthesis, but no increase in
PPARδ transcriptional activity is observed [125]. Thus they
suggest that PGI2 lacks agonistic activity for PPARδ. Since
PGI2 is unstable and rapidly hydrolyzed to 6-keto-PGF1α
within minutes and increases the production of intracellular
cAMP via stimulation of adenylyl cyclase through the cell
surface IP receptor, further investigation is necessary to
certify the mechanism of the eﬀect of the PGI2 on PPARδ
activity in detail. Therefore, additional analyses are necessary
to deﬁne the PPARδ functions in cancer (Figure 2).
4. PPARγ AND CANCER
Cancer cells represent dysregulaton of the cell cycle and lead
to cell proliferation. In this viewpoint, modulators of the cell
cycle and/or apoptosis are useful as chemotherapeutic agents
for cancer [126, 127]. A number of investigators have shown
that PPARγ was expressed in a variety of tumor cells, and
the activation of PPARγ by ligands led to either inhibition
of cell proliferation or induction of apoptosis (Table 2)
[128, 129]. PPARγ is expressed in colonic tumors, normal
colonic mucosa, and colon cancer cell lines [130–135].
Kitamura et al. showed that TZDs, such as troglitazone and
rosiglitazone, inhibited the cell growth and induced G1 cell
cycle arrest of rat intestinal epithelial cells [136]. The cell
growth inhibition by TZDs was caused by the decrease of
the expression of cyclin D1, critical for entering the S phase
of the cell cycle. TZDs suppressed the cyclin D1 promoter
activity through inhibition of the transcriptional activities of
AP-1 and Ets [136]. Shao et al. demonstrated that treatmentKeisuke Tachibana et al. 7
Tumor progression
• Induction of the cell proliferation
• Inhibition of apoptosis
• Up-regulation of VEGF expression
• Enhancement of COX-2 expression
and PGE2 production
Tumor suppression
• Induction of the terminal
diﬀerentiation
• Induction of apoptosis
• Inhibition of the cell growth
Figure 2: Does PPARδ progress or suppress tumor growth?
Table 2: The expression of PPARγ in cancer.
References
Colonic tumor [135]
Breast tumor [137]
Esophageal tumor [138]
Gastric cancer [139]
Pancreatic cancer [140]
Hepatocellular carcinoma [141]
Adrenocortical carcinoma [142]
Lung tumor [143]
Prostate cancer [144]
Liposarcoma [145]
Thyroid carcinoma [146]
Bladder cancer [147]
Renal cell carcinoma [148]
Melanoma [149]
Squamous cell carcinoma [150]
Cervical carcinoma [151]
Testicular cancer [152]
Neuroblastoma [153]
Pituitary tumor [154]
with rosiglitazone inhibited the K-Ras-induced elevation
of the expression levels of cyclin D1 by inhibition of the
K-Ras-induced phosphorylation of Akt, resulting in the G1
cell cycle arrest [89]. Furthermore, J.-A. Kim et al. showed
that treatment of the human colorectal cell line, HCT15,
with troglitazone induced the expression of p21Cip1/Waf1, that
is, a CDK inhibitor (CKI) and negatively regulates the cell
cycle progression, through the ERK pathway, and inhibited
HCT15 cell growth [155]. PPARγ ligands also induce apop-
tosis in human colon cancer cells [156]. Chen et al. sho-
wed that PPARγ ligands, 15-Deoxy-Δ12,14-prostaglandin
J2 (15dPGJ2), or ciglitazone, induced apoptosis in HT-29 by
inhibiting nuclear factor kappa B (NF-κB) activity, which
upregulates various antiapoptotic genes, and suppressing the
expression of BCL-2, which protects cells against apoptosis
[133]. Furthermore, using the in vivo mouse model, the
administrationofTZDtomicereducedAOMand/ordextran
sodium sulfate-induced formation of aberrant crypts foci
and colon carcinogenesis [131, 157]. In addition, PPARγ lig-
ands also inhibit the cell growth of several breast cancer cell
lines and mammary gland tumor development [137, 158–
162]. Elstner et al. showed that PPARγ ligands, troglitazone,
15dPGJ2, and indomethacin, caused inhibition of prolifera-
tion in several human breast cancer cell lines, such as MCF7,
MDA-MB-231, BT474, and T47D [162]. Troglitazone also
inhibited MCF7 tumor growth in triple-immunodeﬁcient
BNX nude mice [162]. Clay et al. reported that 15dPGJ2 and
troglitzaone attenuated cellular proliferation of MDA-MB-
231byblockingcellcycleprogressionandinducingapoptosis
[160]. Pretreatment of MDA-MB-231 cells with 15dPGJ2
attenuated the capacity of these cells to induce tumors in
nude mice [160]. Yin et al. showed that treatment of MCF7
with troglitazone also decreased the expression of several
regulatorsofpRbphosphorylation,suchascyclinD1,CDK4,
CDK6, and CDK2 [158]. pRB is a retinoblastoma tumor
suppressor gene product, and phosphorylated pRB induces
cell cycle progression [163]. Troglitazone induced the G1 cell
cycle arrest by attenuation of pRb phosphorylation, resulting
in inhibition of cell proliferation [158]. Suh et al. showed
that GW7845, synthetic PPARγ ligand, prevented mammary
carcinogenesis in the rat model that used nitrosomethylurea
as the carcinogen [159]. Mehta et al. also reported that
troglitazone prevented the induction of preneoplastic lesions
by 7, 12-dimethylbenz[a]anthracene in a mouse mammary
gland organ culture model [161]. Moreover, PPARγ ligands
inhibit the cell proliferation in other types of cancer. PPARγ
ligands inhibited the growth of esophageal squamous car-
cinoma cell lines by inducing G1 arrest associated with an
increased level of several CKIs, such as p27Kip1,p 2 1 Cip1/Waf1,
and p18Ink4c [138]. PPARγ ligands also induced apoptosis
and G1 cell cycle arrest in human gastric cancer cells,
and that inhibited cell proliferation [139, 164]. In human
pancreatic cancer cells, PPARγ ligands induced apoptosis
and growth inhibition associated with G1 cell cycle arrest
through increasing p27Kip1 protein expression [140, 165–
167]. In human hepatocellular carcinoma cell lines, PPARγ
ligandsinducedcellcyclearrestthroughincreasedexpression8 PPAR Research
of p21Cip1/Waf1,p 2 7 Kip1, and p18Ink4c protein levels [141,
168]. Troglitazone also induced the activation of the cell
death protease, caspase 3, and that induced apoptosis of
human liver cancer cell lines [169]. PPARγ is abundantly
expressedinhumanadrenaltumorsincludingadrenocortical
carcinomas and normal adrenal tissues. PPARγ agonists
suppress adrenocortical tumor cell proliferation, increase
apoptosis, and induce adrenal diﬀerentiation [142, 170].
Moreover, PPARγ ligand showed antitumor eﬀect against
human prostate cancer cells and human lung cancer cells
[143, 144, 171–173]. Thus PPARγ ligands could suppress the
tumorigenesis. Therefore, PPARγ ligands could be used as
antineoplastic drugs.
In contrast, both troglitazone and rosiglitazone treat-
ment increased the frequency and size of colon tumors
in Apcmin mice [174, 175]. Treatment with rosiglitazone
also increased the expression levels of β-catenin, a protein
involved in Wnt signaling and correlating with enhanced
cell proliferation, in the colon of Apcmin mice and HT-29
cells [174]. To investigate the basis for this contradiction,
Girnun et al. used mice heterozygous for PPARγ with both
chemical and genetic models of human colon cancer [176].
Heterozygous loss of PPARγ caused a greater incidence of
colon cancer when these mice were treated with AOM.
Although there was no diﬀerence in β-catenin expression
levels in colorectal tumors between AOM-treated PPARg+/−
and wild-type mice, β-catenin expression levels in the
colonic epithelium of untreated PPARg+/− mice were greater
than that of untreated wild-type mice. When crossing to
Apc1638N mice, the mouse model for FAP, there were also no
diﬀerence in β-catenin levels between PPARg+/−/Apc1638N
and PPARg+/+/Apc1638N mice before polyp formation. Sur-
vival and the number of tumors formed in the colon also
showed no diﬀerence in both mice. Thus although PPARγ
has the potential to suppress β-catenin levels and colon
carcinogenesis, PPARγ has no eﬀect on β-catenin levels or
tumorigenesis in the presence of APC signaling dysfunction
[176]. Furthermore, PPARγ mutations, some of which show
the loss of the transactivation ability, are found in colon
cancers in humans, and that PPARγ may be considered
as a tumor suppressor gene [134]. On the other hand, to
evaluate the contribution of PPARγ to breast cancer, Saez
et al. generated transgenic mice, MMTV-VpPPARγ mice,
that express a constitutively active form of PPARγ in mam-
mary gland [177]. MMTV-VpPPARγ mice showed normal
development of mammary gland and no increased ten-
dency to develop tumors. To assess the inﬂuence of in-
creased PPARγ signaling on mammary gland neoplasia,
MMTV-VpPPARγ mice were crossed to mice that express
a polyoma virus middle T antigen (PyV-MT) in mammary
tissue, MMTV-PyV mice, which rapidly develop tumors.
These mice that expressed both activated PPARγ and PyV-
MT showed accelerated development of mammary tumors.
Therefore, although increased PPARγ activation does not
initiate tumor formation in normal mammary tissue, once
a tumor-initiating event occurs, PPARγ signaling serves as a
tumor promoter in the mammary gland. Furthermore, there
is no diﬀerence in tumor development between MMTV-PyV
mice and the mice, generated by crossing PPARg+/− mice to
MMTV-PyVmice[177].Thusinthismodel,PPARγ doesnot
act as a tumor suppressor gene.
Furthermore, PPARγ ligands exert their biological eﬀects
through a PPARγ-independent pathway. Palakurthi et al.
reported that troglitazone and ciglitazone induced G1 arrest
by inhibiting translation initiation in both PPARg
−/− and
PPARg+/+ mouse embryonic stem cells. Thus TZDs inhibit
cellproliferationandtumorgrowthinaPPARγ-independent
manner [178]. Therefore, although PPARγ ligands are used
as insulin sensitizers, further investigation is needed to clar-
ify whether PPARγ ligands are eﬀective chemotherapeutic
agents for cancer in humans.
5. SUMMARY
PPARs are linked to metabolic disorders and are interesting
pharmaceuticaltargets.Amongthesyntheticligands,ﬁbrates
are hypolipidemic compounds that activate PPARα,a n d
TZDs, which selectively activate PPARγ,a r eh y p o g l y c a e m i c
molecules that are used to treat type 2 diabetes. PPARδ
agonists might form eﬀective drugs for obesity, diabetes, and
cardiovascular disease. Moreover, recent evidence suggests
that PPAR modulators may have beneﬁcial eﬀects as chemo-
preventive agents [179]. However, as mentioned above, it
remains unclear whether PPARs act as oncogenes or as
tumor suppressors. From this viewpoint, current strategies
are aimed at reducing the side eﬀects and improving the
eﬃcacy and safety proﬁle of PPAR agonists, termed selec-
tive PPAR modulators (SPPARMs) [180, 181]. This model
proposes that SPPARMs bind in distinct manners to the
ligand binding pocket of PPAR and induce distinct confor-
mational changes of the receptor, resulting in diﬀerential
interactions with cofactors according to the combination
of their expression levels in diﬀerent organs. Thus each
SPPARM leads to diﬀerential gene expression and biological
response. However, what kinds of cofactors are recruited
to PPAR by each SPPARM is still unknown. Thus it is
important to identify the cofactor complex for PPAR with
each SPPARM and the expression patterns of cofactors in
various tissues. Furthermore, recent evidence suggests that
the ligand binding protein in the cytosol that transports
ligands into the nucleus is important to modulate the action
of nuclear receptors. Long-chain fatty acids, endogenous
PPAR ligands, are highly hydrophobic and fatty acids are
bound to fatty acid binding proteins (FABPs) in the aqueous
intracellular compartment [182]. FABPs also bind to PPAR
ligands and transport them from the cytosol into the nucleus
[183–191]. In the nucleus, FABPs interact directly with
PPARs and deliver ligands to PPARs, and the activity of
PPARs is modulated [186, 187, 190–192]. Recently, Schug
et al. showed that when the cellular retinoic acid binding
protein-II (CRABP-II) expression levels were higher than
FABP5 in the cells, retinoic acid (RA) bound to CRABP-
II. Subsequently, CRABP-II relocated to the nucleus and
delivered RA to RAR, resulting in inhibition of cell pro-
liferation and induction of apoptosis [187, 193]. On the
contrary, when the FABP5 to CRABP-II ratio is high, RA
serves as a physiological ligand for PPARδ, which induces
cell survival and proliferation [187, 194]. Therefore, it isKeisuke Tachibana et al. 9
important to identify the cytosolic ligand binding proteins
and the expression levels of the proteins for deﬁning the
physiological eﬀects of ligands. Furthermore, several ligands
exert their biological eﬀects through a PPAR-independent
pathway [195]. Thus further studies are required to elucidate
the role of PPARs for developing new eﬃciently and safety
chemotherapeutic agents for cancer.
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